An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model.

Castrate Resistant ◽

235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model

European Urology Supplements ◽

10.1016/s1569-9056(12)60232-2 ◽

2012 ◽

Vol 11 (1) ◽

pp. e235

Author(s):

H. Matsumoto ◽

H. Kuruma ◽

A. Zoubeidi ◽

A. Zardan ◽

L. Fazli ◽

...

Keyword(s):

Prostate Cancer ◽

Second Generation ◽

Cancer Model ◽

Castrate Resistant ◽

125 CLUSTERIN ANTISENSE INHIBITOR OGX-011 SYNERGIZES ACTIVITY OF SECOND GENERATION ANTI-ANDROGEN, MDV3100, IN CASTRATE RESISTANT PROSTATE CANCER MODEL

The Journal of Urology ◽

10.1016/j.juro.2011.02.192 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Hiroaki Matsumoto ◽

Hidetoshi Kuruma ◽

Amina Zoubeidi ◽

Ladan Fazli ◽

Martin Gleave

Keyword(s):

Prostate Cancer ◽

Second Generation ◽

Cancer Model ◽

Castrate Resistant ◽

Abstract 2640: Characterization and targeted therapy using patient tumor-derived 3-D spheroids in a metastatic castrate resistant prostate cancer model

10.1158/1538-7445.am2021-2640 ◽

2021 ◽

Author(s):

Adam M. Kase ◽

Winston Tan ◽

John A. Copland

Keyword(s):

Prostate Cancer ◽

Targeted Therapy ◽

Cancer Model ◽

Castrate Resistant ◽

The clinical outcome of second generation anti-hormonal therapy in patients with metastatic castrate-resistant prostate cancer following CHAARTED regimen.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e17044 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e17044-e17044 ◽

Cited By ~ 1

Author(s):

Jaspreet Chahal ◽

Thomas Paul Bradley ◽

Cristina Sison ◽

Xinhua Zhu

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Hormonal Therapy ◽

Second Generation ◽

Castrate Resistant

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-13-1026 ◽

2013 ◽

Vol 19 (22) ◽

pp. 6205-6218 ◽

Cited By ~ 58

Author(s):

Andressa Ardiani ◽

Benedetto Farsaci ◽

Connie J. Rogers ◽

Andy Protter ◽

Zhimin Guo ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Combination Therapy ◽

Receptor Antagonist ◽

Second Generation ◽

Cancer Model ◽

Androgen Receptor Antagonist ◽

Abstract 5376: Antisense oligonucleotide targeting insulin-like growth factor-1 receptor (IGF-1R) enhances paclitaxel sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer model

10.1158/1538-7445.am10-5376 ◽

2010 ◽

Author(s):

Junya Furukawa ◽

Christopher J. Wraight ◽

Brett P. Monia ◽

Martin E. Gleave ◽

Michael E. Cox

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Antisense Oligonucleotide ◽

Insulin Like Growth Factor ◽

Cancer Model ◽

Castrate Resistant ◽

234 Antisense oligonucleotide targeting Insulin-like Growth Factor-1 Receptor (IGF-1R) enhances paclitaxel sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer model

European Urology Supplements ◽

10.1016/s1569-9056(12)60231-0 ◽

2012 ◽

Vol 11 (1) ◽

pp. e234 ◽

Cited By ~ 1

Author(s):

J. Furukawa ◽

H. Miyake ◽

M. Fujisawa

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Antisense Oligonucleotide ◽

Insulin Like Growth Factor ◽

Cancer Model ◽

Castrate Resistant ◽

1113: Route of Administration Influences the Antitumor Effect of Bone Marrow Derived Dendritic Cells Engineered to Produce Interleukin-12 in A Metastatic Mouse Prostate Cancer Model

The Journal of Urology ◽

10.1016/s0022-5347(18)38350-2 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 293-294

Author(s):

Takashi Saika ◽

Takefumi Satoh ◽

Nobuyuki Kusaka ◽

Shin Ebara ◽

Vladimir B. Mouraviev ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Marrow ◽

Dendritic Cells ◽

Antitumor Effect ◽

Route Of Administration ◽

Interleukin 12 ◽

Cancer Model ◽

Mouse Prostate ◽

Combined AR phosphorylation at serine 81 and serine 213 are associated with decreased survival in Castrate Resistant Prostate Cancer

Endocrine Abstracts ◽

10.1530/endoabs.42.p20 ◽

2016 ◽

Author(s):

Milly J McAllister ◽

Pamela McCall ◽

Mark A Underwood ◽

Hing Y Leung ◽

Joanne Edwards

Keyword(s):

Prostate Cancer ◽

Castrate Resistant

the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Case Medical Research ◽

10.31525/ct1-nct03899467 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Castrate Resistant